ERCC2 and esophageal cancer: As far as we know, several previous meta-analyses on XPD Lys751Gln polymorphism and cancers risk have been performed, such as gastric cancer, colorectal cancer, esophageal cancer, breast cancer and bladder cancer [14]–[23].